ProKidney (Nasdaq: PROK), a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, REACT™ (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases potentially drive meaningful improvement in kidney function. Late-stage CKD, Stage 3b - 4, is a key target for REACT™ therapy. REACT™ has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022. For more information, visit www.prokidney.com.

Biotechnology

Health Care

Life Sciences

Medical Devices

Therapeutics

ProKidney Corp.

Bruce Culleton

Director, ASAT

Carla Poulson

Kathleen Conde

Anu Biswas

Brian Buckley

James Coulston

Clarence W. Baker

Nancy Fuselli

McKenzie Christopher Pitts

Mary M. Weger

Emily Butler

Aparna Sahoo

Todd Girolamo

Nikhil Pereira-Kamath

The Clinical and Quality Assurance Team at ProKidney Corp. is responsible for overseeing and ensuring the adherence to clinical protocols and regulatory standards throughout the development and trial phases of REACT™ therapy. This team coordinates clinical trials, manages data integrity, ensures compliance with FDA and EMA guidelines, and maintains high-quality standards in cellular therapy production. Their work is crucial in advancing ProKidney's innovations safely and effectively from research to patient treatment.

Clinical and Quality Assurance Team

Leadership Team

Manufacturing and Supply Chain

Clinical and Quality Assurance Team

About

Team members

Other teams at ProKidney Corp.

Leadership Team

Manufacturing and Supply Chain